- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Investigational PDTs in Schizophrenia
Panelists discuss how CT-155, a 16-week interactive digital application, met its primary end point in clinical trials by successfully improving experiential symptoms of schizophrenia compared with a control app, with an excellent safety profile.
EP: 1.Discussing Negative Symptoms of Schizophrenia
EP: 2.The Clinical Burden of Negative Symptoms
EP: 3.Exploring the Shortage of Psychiatrists
EP: 4.The Potential of Prescription Drug Therapeutics (PDTs) in Schizophrenia
EP: 5.The Role of PDTs in Clinical Practice
EP: 6.Examining the CONVOKE Clinical Trial
EP: 7.The Future of Pharmacotherapy Plus PDTs
EP: 8.Economic Burden Associated With Schizophrenia
EP: 9.Key Background Information on Prescription Digital Therapeutics
EP: 10.Insurance Coverage of Prescription Digital Therapeutics
EP: 11.Managed Care Considerations for Prescription Digital Therapeutics
EP: 12.The Role of Advanced Practice Providers in Mental Health
EP: 13.Managing Negative Symptoms Associated With Schizophrenia
EP: 14.Current PDTs in Mental Health Disorders
EP: 15.Utilizing PDTs in the Future for Negative Symptoms
EP: 16.Using PDTs in Rural Areas
EP: 17.Combining PDTs With Antipsychotic Medications
EP: 18.Investigational PDTs in Schizophrenia
EP: 19.Patient Experience with PDTs
Patients participating in clinical trials for CT-155 have provided valuable insights into the potential benefits of prescription digital therapeutics (PDTs) for negative symptoms of schizophrenia. This investigational app delivers interactive psychosocial interventions through smartphones over a 16-week period, adapting to individual patient responses to provide personalized therapeutic experiences. Patients can access these interventions at any time of day, providing flexibility and immediate availability that traditional therapy cannot offer.
The CONVOKE clinical trial demonstrated significant benefits for patients using CT-155 compared with those using a control app without therapeutic interventions. Patients in the treatment group showed meaningful improvements in experiential symptoms of schizophrenia while maintaining an excellent safety profile with no significant adverse events. This evidence provides hope for patients who have limited effective treatment options for negative symptoms that significantly impact their daily functioning.
For patients with schizophrenia, particularly younger individuals who are comfortable with technology, CT-155 represents a potentially transformative treatment option. The app’s design recognizes that patients today, especially those diagnosed in their late teens to mid-20s, have grown up with smartphones and are likely to find digital interventions more acceptable than traditional medications with potential adverse effects. Patients deserve access to innovative treatments that leverage familiar technology to address the complex psychological and social challenges of schizophrenia.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
